Lishan Wang1. 1. Bio-X Institutes, Key Laboratory for the Genetics of Developmental and Neuropsychiatric Disorders (Ministry of Education), Shanghai Jiao Tong University, Shanghai, P.R. China ; FengHe (ShangHai) Information Technology Co., Ltd, Shanghai, P.R. China.
Abstract
BACKGROUND: Drug-eluting stents (DES) are increasingly used for treatment of acute coronary syndrome (ACS). However, clinical efficacy and safety of various types of DES is not well established in these subjects. We therefore evaluated clinical utility of second-generation and first-generation DES in patients with ACS by conducting a meta-analysis. METHODS: A search of Medline, Embase, the Cochrane databases, and Web of Science was made. Randomized controlled trials (RCTs) which compared second-generation DES (everolimus-eluting stents [EES] or zotarolimus-eluting stents [ZES]) versus first-generation DES (sirolimus-eluting stents [SES] or paclitaxe-eluting stents [PES]) in patients with ACS and provided data on clinical efficacy or safety endpoints were included. Pooled estimates were calculated using random-effects model. RESULT: A total of 2,757 participants with ACS in 6 RCTs were included. Compared with first-generation one, second-generation DES trended to be associated with the decreased incidence of definite or probable stent thrombosis in ACS patients (risk ratio [RR] = 0.60, 95% confidence intervals [CI] 0.33 to 1.07, p = 0.09). However, the rate of target lesion revascularization (TLR) significantly increased in second-generation DES (RR = 2.08, 95%CI 1.25 to 3.47, p = 0.005). There were no significant differences in the incidence of major adverse cardiac events (MACEs), all-cause death, cardiac death, and recurrent myocardial infarction between the two arms (all p>0.10). The second-generation EES showed a tendency towards lower risk of MACEs (p = 0.06) and a beneficial effect on reducing stent thrombosis episodes (p = 0.009), while the second-generation ZES presented an increased occurrence of MACEs (p = 0.02) and TLR (p = 0.003). CONCLUSION: Second-generation DES, especially EES, appeared to present a lower risk of stent thrombosis, whereas second-generation ZES might increase the need for repeat revascularization in ACS patients. During coronary interventional therapy, DES class should be adequately considered in order to maximize clinical benefit of DES implantation in these specific subjects.
BACKGROUND: Drug-eluting stents (DES) are increasingly used for treatment of acute coronary syndrome (ACS). However, clinical efficacy and safety of various types of DES is not well established in these subjects. We therefore evaluated clinical utility of second-generation and first-generation DES in patients with ACS by conducting a meta-analysis. METHODS: A search of Medline, Embase, the Cochrane databases, and Web of Science was made. Randomized controlled trials (RCTs) which compared second-generation DES (everolimus-eluting stents [EES] or zotarolimus-eluting stents [ZES]) versus first-generation DES (sirolimus-eluting stents [SES] or paclitaxe-eluting stents [PES]) in patients with ACS and provided data on clinical efficacy or safety endpoints were included. Pooled estimates were calculated using random-effects model. RESULT: A total of 2,757 participants with ACS in 6 RCTs were included. Compared with first-generation one, second-generation DES trended to be associated with the decreased incidence of definite or probable stent thrombosis in ACS patients (risk ratio [RR] = 0.60, 95% confidence intervals [CI] 0.33 to 1.07, p = 0.09). However, the rate of target lesion revascularization (TLR) significantly increased in second-generation DES (RR = 2.08, 95%CI 1.25 to 3.47, p = 0.005). There were no significant differences in the incidence of major adverse cardiac events (MACEs), all-cause death, cardiac death, and recurrent myocardial infarction between the two arms (all p>0.10). The second-generation EES showed a tendency towards lower risk of MACEs (p = 0.06) and a beneficial effect on reducing stent thrombosis episodes (p = 0.009), while the second-generation ZES presented an increased occurrence of MACEs (p = 0.02) and TLR (p = 0.003). CONCLUSION: Second-generation DES, especially EES, appeared to present a lower risk of stent thrombosis, whereas second-generation ZES might increase the need for repeat revascularization in ACS patients. During coronary interventional therapy, DES class should be adequately considered in order to maximize clinical benefit of DES implantation in these specific subjects.
Authors: Roberto Martín-Reyes; Raul Moreno; Angel Sánchez-Recalde; Felipe Navarro; Juan Franco; Antonio Piñero; José Luis López Sendón Journal: Int J Cardiol Date: 2011-05-04 Impact factor: 4.164
Authors: Gregg W Stone; Ali Rizvi; William Newman; Kourosh Mastali; John C Wang; Ronald Caputo; Julie Doostzadeh; Sherry Cao; Charles A Simonton; Krishnankutty Sudhir; Alexandra J Lansky; Donald E Cutlip; Dean J Kereiakes Journal: N Engl J Med Date: 2010-05-06 Impact factor: 91.245
Authors: Troels Thim; Michael Maeng; Anne Kaltoft; Lisette O Jensen; Hans H Tilsted; Peter R Hansen; Henning Kelbaek; Per Thayssen; Jan Ravkilde; Morten Madsen; Henrik T Sørensen; Leif Thuesen; Jens F Lassen Journal: Eur J Clin Invest Date: 2012-05-24 Impact factor: 4.686
Authors: Giuseppe De Luca; Maurits T Dirksen; Christian Spaulding; Henning Kelbaek; Martin Schalij; Leif Thuesen; Bas van der Hoeven; Marteen A Vink; Christoph Kaiser; Carmine Musto; Tania Chechi; Gaia Spaziani; Luis Salvador Díaz de la Llera; Vincenzo Pasceri; Emilio Di Lorenzo; Roberto Violini; Giuliana Cortese; Harry Suryapranata; Gregg W Stone Journal: Arch Intern Med Date: 2012-04-23
Authors: Gregg W Stone; Jeffrey W Moses; Stephen G Ellis; Joachim Schofer; Keith D Dawkins; Marie-Claude Morice; Antonio Colombo; Erick Schampaert; Eberhard Grube; Ajay J Kirtane; Donald E Cutlip; Martin Fahy; Stuart J Pocock; Roxana Mehran; Martin B Leon Journal: N Engl J Med Date: 2007-02-12 Impact factor: 91.245
Authors: Manel Sabate; Angel Cequier; Andrés Iñiguez; Antonio Serra; Rosana Hernandez-Antolin; Vicente Mainar; Marco Valgimigli; Maurizio Tespili; Pieter den Heijer; Armando Bethencourt; Nicolás Vazquez; Joan Antoni Gómez-Hospital; José Antonio Baz; Victoria Martin-Yuste; Robert-Jan van Geuns; Fernando Alfonso; Pascual Bordes; Matteo Tebaldi; Monica Masotti; Antonio Silvestro; Bianca Backx; Salvatore Brugaletta; Gerrit Anne van Es; Patrick W Serruys Journal: Lancet Date: 2012-09-03 Impact factor: 79.321
Authors: Damian Kawecki; Beata Morawiec; Janusz Dola; Wojciech Wanha; Grzegorz Smolka; Aleksandra Pluta; Kamil Marcinkiewicz; Andrzej Ochała; Ewa Nowalany-Kozielska; Wojciech Wojakowski Journal: Arq Bras Cardiol Date: 2016-04-05 Impact factor: 2.000